Why the study?
Does the Lumi-Aggregometer ATP release assay accurately diagnose bleeding disorders or inherited platelet function disorders in people tested for ATP release defects?
Does the Lumi-Aggregometer ATP release assay accurately diagnose bleeding disorders or inherited platelet function disorders in people tested for ATP release defects?
The Lumi-Aggregometer ATP release assay is highly specific and moderately sensitive for diagnosing inherited platelet function disorders, even when platelet aggregation is normal.
May support ATP release testing in bleeding evaluations; leaves open prospective validation before routine diagnostic adoption.
Platelet dense granule release assays are recommended for diagnosing platelet function disorders and are commonly performed by Lumi-Aggregometer (Chrono-Log, Havertown, PA) assays of adenosine triphosphate (ATP) release. We conducted a prospective cohort study of people tested for ATP release defects to assess bleeding symptoms. Reduced release, with 1 or more agonists, was more common among patients with bleeding disorders than among healthy control subjects (P < .001). The respective likelihood (odds ratio [95% confidence interval]) of a bleeding disorder or an inherited platelet function disorder were high when release was reduced with 1 or more agonists (17 [6-46]; 128 [30-545]), even if aggregation was normal (12 [4-34]; 105 [20-565]). ATP release had high specificity and moderate sensitivity for inherited platelet function disorders, with most abnormalities detected by the combination of 6 μmol/L epinephrine, 5.0 μg/mL collagen, and 1 μmol/L U46619. Platelet ATP release assays are useful for evaluating common bleeding disorders, regardless of aggregation findings.
No takes yet. Share an insight, caveat, or question.
Pai et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: